Skip to main content

Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
Chemotherapy

A literature review revealed that there are many mechanisms of drug resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small-cell cell lung cancer.

CTD²
Annual Review of Pathology: Mechanisms of Disease

This review discusses the pros, cons and recent advances of organoids as tumor models.

CTD²
Journal of the American Chemical Society

Researchers illustrate a novel way of using isotopically enhanced two-dimensional NMR spectroscopy to interrogate reaction mechanisms as they occur.

CTD²
Proceedings of the Pacific Symposium on Biocomputing 2016

The authors incorporated existing knowledge of gene interactions to generate more accurate statistical predictions of gene interaction networks.

CTD²
Molecular Cancer Research

An shRNA screen identified the only lung cancer cell line in the panel to be sensitive to knockdown of MAP2K1 and thus sensitive to MEK1 inhibition.

CTD²
Nature Chemical Biology

Expression of cytochrome P450 makes cell lines sensitive to oxalamides and benzothiazoles.

CTD²
Nature Chemical Biology

These results implicate PDE3A modulators as candidate cancer therapeutic agents and demonstrate the power of predictive chemogenomics in small-molecule discovery.

CTD²
Scientific Reports

Researchers describe methodology for detailed studies of human Neural crest cells (NCC), and clarifies roles for retinoids and bone morphogenetic proteins in the differentiation of human pluripotent stem cells to trunk NCC and to sympathoadrenal lineages.

CTD²
Nature Communications

The authors use a gain-of-function screening platform to clone and functionally assess mutations that occur at low frequency in pancreatic cancer

CTD²
Bioinformatics

Investigators develop an algorithm to statistically analyze off-target effects of RNAi and CRISPR screens.